GSK Shoulder-To-Shoulder With CureVac Over COVID-19 Vaccine U-Turn
Focus On Second-Generation After EMA Filing Withdrawal
The UK major is delighted with the German biotech's decision to throw in the regulatory towel with CVnCoV and concentrate on the firms' collaboration to development a second-generation COVID-19 vaccine. However, GSK is insisting that the partners look at both modified as well as unmodified mRNA approaches, a significant change of strategy for CureVac.
You may also be interested in...
An online gaming entrepreneur is injecting new cash and strategic thinking into biotech Ethris – with the goal of making it a ‘gamechanger’ in inhaleable mRNA.
Phil Dormitzer has been headhunted to help GSK get up to speed in RNA and other vaccine platforms.
The menopause drug elinzanetant, which has just gone into Phase III, has joined Kerendia, Verquvo and Nubeqa as a candidate that Bayer believes has a peak sales potential of more than €1bn.